A-PHP is known to produce increased heart rate, a physical effect. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Increased heart rate, clinically termed tachycardia when exceeding 100 beats per minute at rest, manifests as a heightened awareness of one's own cardiac rhythm. At lower intensities, users may simply notice their pulse feels slightly faster than baseline—a faint thumping sensation in the chest or a mild warmth spreading through the torso. At higher intensities, the heartbeat becomes impossible to ignore: a powerful, rapid drumming that can be felt in the throat, wrists, and behind the eyes, sometimes accompanied by visible pulsation of veins and a sensation of the heart "trying to escape" the ribcage.
The intensity of this effect follows a clear dose-dependent curve. At threshold doses of stimulants or psychedelics, heart rate may increase by only 5-15 BPM above baseline—barely perceptible without deliberately checking one's pulse. At moderate doses, increases of 20-40 BPM become noticeable during both activity and rest, often accompanied by a subtle chest tightness. At high doses or during combinations, heart rate can spike to 140-180+ BPM, producing significant discomfort, breathlessness, and anxiety that may trigger panic responses that further compound the tachycardia.
Several distinct subtypes exist. Stimulant-induced tachycardia tends to feel "electric" and buzzing, as if the heart is running at high RPM but smoothly. Psychedelic tachycardia is often intermittent and closely tied to emotional state—surges of awe or anxiety produce momentary spikes. Cannabinoid-induced increases feel more diffuse and are frequently accompanied by postural hypotension. Dissociative tachycardia is often less consciously noticed due to the analgesic and detaching properties of these substances, making it particularly insidious.
Pharmacologically, increased heart rate results from several mechanisms: direct sympathomimetic activation (as with amphetamines and cocaine, which increase catecholamine release), vagal nerve suppression (as with anticholinergic compounds), peripheral vasodilation triggering baroreceptor-mediated compensatory tachycardia (as with cannabis and some psychedelics), or direct agonism at cardiac beta-adrenergic receptors. Serotonergic compounds can also produce tachycardia via 5-HT2A and 5-HT2B receptor activation.
This effect is most prominently associated with stimulants (amphetamines, cocaine, MDMA, caffeine), but it is also common with psychedelics (LSD, psilocybin, mescaline), cannabinoids (THC), dissociatives (PCP, ketamine at higher doses), and empathogens. Essentially, any substance that activates the sympathetic nervous system or suppresses parasympathetic tone can produce it.
From a harm reduction perspective, increased heart rate becomes dangerous when sustained at very high levels, in individuals with pre-existing cardiac conditions, or when combined with other cardiotoxic substances. The combination of stimulants with MAOIs or other stimulants poses particular risk for hypertensive crisis. Users experiencing tachycardia should avoid further stimulant intake, remain hydrated, practice slow breathing techniques, and seek medical attention if heart rate exceeds 150 BPM at rest or is accompanied by chest pain, irregular rhythm, or difficulty breathing.
Increased heart rate can manifest at varying intensities depending on the dose of A-PHP and individual sensitivity. The following levels describe the typical progression of this effect.
A subtle awareness of one's heartbeat, only noticeable when paying attention. Heart rate increased by 5-15 BPM above baseline.
Heart rate is clearly elevated and noticeable during rest. Mild warmth in the chest. Increase of 15-30 BPM.
A pronounced, forceful heartbeat felt in the chest, neck, and wrists. Accompanied by mild breathlessness. Increase of 30-50 BPM.
Rapid, pounding heartbeat that dominates body awareness. Visible pulsation in veins. Accompanied by anxiety and chest tightness. 50-70+ BPM above baseline.
An extremely rapid, forceful heartbeat exceeding 150 BPM at rest. May feel chaotic or irregular. Accompanied by significant distress, breathlessness, and potential medical danger.
A-PHP's mechanism of action is not fully characterized in the scientific literature, but it is believed to act primarily as a potent norepinephrine-dopamine reuptake inhibitor (NDRI) based on its structural similarity to A-PVP and MDPV. Like other pyrrolidine cathinones, it likely functions by binding to the dopamine transporter (DAT) and norepinephrine transporter (NET), blocking the reuptake of dopamine and norepinephrine from the synaptic cleft back into the presynaptic neuron.
Critically, A-PHP is not believed to be a transporter substrate — meaning it does not cause active neurotransmitter release in the manner of amphetamine or methcathinone. This distinction is pharmacologically significant: rather than flooding synapses with newly synthesized neurotransmitter, it prolongs the action of dopamine and norepinephrine already present. This mechanism is more similar to cocaine (which is also primarily a reuptake inhibitor) than to amphetamine.
Unlike entactogenic cathinones in the MDxx family (butylone, ethylone, methylone), A-PHP appears to have minimal serotonin transporter (SERT) activity. This explains the absence of the empathogenic and emotional qualities associated with MDMA-like cathinones, and the more purely stimulant/euphoric character of the experience.
A-PHP is significantly more potent by weight than amphetamine-class stimulants. Active doses are typically in the low milligram range. When vaporized, onset is within seconds and peak effects occur within 1–3 minutes; when insufflated, onset is 2–5 minutes. Duration of peak effects is notably short — 30–60 minutes — which is a primary driver of the compulsive redosing pattern. Total duration including residual stimulation is 2–4 hours per administration.
Tolerance develops rapidly with repeated dosing, often within a single session. The brief duration combined with rapid tolerance development creates a pharmacological pressure toward dose escalation and binge use. The dopaminergic rebound following cessation of high-dose use produces acute dysphoria, anhedonia, and fatigue that can persist for days — the neurobiological substrate of the post-binge "crash."
A-PHP can be administered via insufflated, oral, smoked. The route of administration can influence both the onset and intensity of increased heart rate.
The intensity of increased heart rate depends heavily on the dose of A-PHP. Effects like increased heart rate are typically reported at common to strong doses. Below is the full dosage chart for A-PHP.
Warning
Sustained heart rates above 150 BPM can strain the cardiovascular system and may trigger arrhythmias in susceptible individuals. This effect is particularly dangerous when combining stimulants, in people with pre-existing heart conditions, or with substances that prolong the QT interval. Seek medical attention for chest pain, irregular rhythm, or sustained extreme tachycardia.
Yes. Increased heart rate is a documented physical effect of A-PHP. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
Effects like increased heart rate are typically reported at common doses and above. A common insufflated dose of A-PHP is 5–15 mg.
Other substances documented to produce increased heart rate include Amphetamine, Cocaine, MDMA, Cannabis, Caffeine, and 35 more.
